Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Nurix Therapeutics, Inc. (NRIX)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 47,040,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $ - $
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other diseases. Co.'s Bruton's tyrosine kinase (BTK) degrader drug candidates, NX-2127 and NX-5948, are orally available chimeric targeting molecules for the treatment of relapsed or refractory B-cell malignancies and autoimmune indications. Co.'s drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally bioavailable Casitas B-lineage lymphoma proto-oncogene B inhibitor for immuno-oncology indications.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 15,218 35,430 43,924 56,372
Total Sell Value $172,193 $362,771 $427,193 $583,289
Total People Sold 3 3 3 4
Total Sell Transactions 5 10 16 32
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 173
  Page 4 of 7  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-12-01 4 AS $29.13 $11,652 D/D (400) 14,197     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-12-01 4 OE $7.26 $2,904 D/D 400 14,597     -
   Ring Christine General Counsel   •       –      –    2021-11-10 4 AS $32.38 $38,856 D/D (1,200) 1,286     -
   Ring Christine General Counsel   •       –      –    2021-11-10 4 OE $1.86 $2,232 D/D 1,200 2,486     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-11-01 4 AS $33.24 $13,296 D/D (400) 14,197     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-11-01 4 OE $7.26 $2,904 D/D 400 14,597     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-10-27 4 AS $35.00 $14,000 D/D (400) 14,197     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-10-27 4 OE $7.26 $2,904 D/D 400 14,597     -
   Ring Christine General Counsel   •       –      –    2021-10-27 4 AS $35.25 $28,200 D/D (800) 1,286     -
   Ring Christine General Counsel   •       –      –    2021-10-27 4 OE $1.86 $1,488 D/D 800 2,086     -
   Ring Christine General Counsel   •       –      –    2021-10-11 4 AS $27.36 $32,832 D/D (1,200) 1,286     -
   Ring Christine General Counsel   •       –      –    2021-10-11 4 OE $1.86 $2,232 D/D 1,200 2,486     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-10-01 4 AS $29.92 $11,968 D/D (400) 14,197     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-10-01 4 OE $7.26 $2,904 D/D 400 14,597     -
   Ring Christine General Counsel   •       –      –    2021-09-10 4 AS $35.10 $71,860 D/D (2,000) 1,286     -
   Ring Christine General Counsel   •       –      –    2021-09-10 4 OE $1.86 $3,720 D/D 2,000 3,286     -
   Ring Christine General Counsel   •       –      –    2021-09-07 4 AS $35.25 $112,800 D/D (3,200) 1,286     -
   Ring Christine General Counsel   •       –      –    2021-09-07 4 OE $1.86 $5,952 D/D 3,200 4,486     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-09-07 4 AS $35.00 $56,000 D/D (1,600) 14,197     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-09-07 4 OE $7.26 $11,616 D/D 1,600 15,797     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-09-01 4 AS $32.34 $12,936 D/D (400) 14,197     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-09-01 4 OE $7.26 $2,904 D/D 400 14,597     -
   Ring Christine General Counsel   •       –      –    2021-08-10 4 AS $29.87 $35,845 D/D (1,200) 805     -
   Ring Christine General Counsel   •       –      –    2021-08-10 4 OE $1.86 $2,232 D/D 1,200 2,005     -
   Beaurang Pierre Chief Business Officer   •       –      –    2021-08-10 4 AS $29.74 $223,926 D/D (7,500) 4,330     -
  173 Records found
  1  2  3  4  5  6  7   
  Page 4 of 7
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us